Regencell Bioscience Holdings (RGC) IPO Opens 26% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street mixed as oil prices surge, investors await earnings, economic data
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Regal Entertainment Group (RGC) Prices 2.3M Share IPO at $9.5/sh
July 15, 2021 6:06 PM EDTRegencell Bioscience Holdings Limited (NASDAQ: RGC) an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July... More



